Jakob Dupont - 02 Nov 2021 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Role
EVP, Head of R&D
Signature
/s/ Nimit Arora, Attorney-in-Fact for Jakob Dupont
Issuer symbol
ATRA
Transactions as of
02 Nov 2021
Net transactions value
-$34,150
Form type
4
Filing time
04 Nov 2021, 16:10:09 UTC
Previous filing
19 Aug 2021
Next filing
18 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATRA Common Stock Options Exercise $47,900 +5,000 +5.4% $9.58 97,793 02 Nov 2021 Direct F1
transaction ATRA Common Stock Sale $82,050 -5,000 -5.1% $16.41* 92,793 02 Nov 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATRA Employee Stock Option (Right to Buy) Options Exercise $0 -5,000 -1.8% $0.000000 272,500 02 Nov 2021 Common Stock 5,000 $9.58 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021.
F2 25% of the shares subject to the option vest on May 14, 2021 and the remaining shares vest in equal monthly installments over the following 36 months, subject to the reporting person's continuous service.